Major marijuana multistate operator Curaleaf Holdings posted $345.3 million in net revenue for the fourth quarter of 2023, an increase of 1.5% over the same quarter the year before and 3.6% over the third quarter.
Curaleaf International has acquired Polish medical cannabis operator Can4Med, giving the London-based company a foothold in one of Europe’s most promising medical marijuana markets.
Somai Pharmaceuticals said it received European Union-Good Manufacturing Practice (EU-GMP) certification from the Portuguese health authority Infarmed.
The U.S. Stock Exchange represents a global income source for private investors and investment funds worldwide. Until not so very long ago, investors’ focus was limited to the technology sector, which is strategically vital to the U.S. economy overall.
Toronto-based Ramm Pharma Corp. acquired HemPoland from The Green Organic Dutchman Holdings for 1.2 million Canadian dollars ($910,000) in cash.
The largest CBD companies in the U.S. experienced declining market share in the second quarter, as the return of in-person shopping triggered a decline in e-commerce sales.
Market share by revenue for the top 20 CBD brands shrank 2 percentage points, to 16%, versus the first quarter of the year, according to Chicago-based cannabis analytics firm Brightfield Group.
Germany is forging ahead with plans to establish Europe’s first national recreational cannabis market, but details about the rules that will govern the industry remain scarce.
Enecta co-founder and Chief Science Officer Jacopo Paolini discusses how his company developed a certified cannabinoid variety and how long it will take to see other cannabinoid-producing plants win government approval,
Although roughly half of New York’s municipal governments opted out of permitting recreational cannabis stores before a Dec. 31 deadline, those opt-outs aren’t set in stone.
Opening a retail cannabis store is difficult. Throw in a pandemic, Toronto’s bitterly cold winter weather or the revival of a dormant medical marijuana dispensary, and the new venture could be headed for disaster.
Investors as well as cannabis companies and executives are rushing into psychedelics, a multibillion-dollar opportunity that reminds some of the early days of marijuana – although this infant industry could play out much differently.
